Durin Technologies develops non-invasive, easy access diagnostic tests for the most prevalent and devastating neurodegenerative disorders, including Alzheimer's and Parkinson's diseases.​ Its rapid-result, high-accuracy DuritectTM diagnostic tests make early detection and monitoring of disease progression possible – in a decade or more prior to symptoms in some cases. Durin’s first two tests – for Alzheimer's and Parkinson’s – will come to market in 2024, followed by tests for other diseases.​ The company’s groundbreaking science creates a scalable platform for diagnostic tests that will extend beyond the multi-billion-dollar neurodegenerative diagnostics market into the much larger, broader disease diagnostic market.​